Tenderwize
Retour à la recherche

Open House Drug Discount Agreements Budesonid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2027 · 278 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Budesonid, ATC A07EA06

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

Open-house agreements may be superseded by other discount contracts, causing early termination without compensation.

Strict submission requirements (paper originals, qualified electronic signature, monthly deadlines) could slow down con...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive drug discount agreements for Budesonid (ATC A07EA06) with AOK Bayern.
  • All interested pharmaceutical companies meeting eligibility may join at any time until 03.06.2027.
Afficher le résumé complet

Open-house model for non-exclusive drug discount agreements (Budesonid, ATC A07EA06) with AOK Bayern. Not a formal procurement procedure; any eligible pharmaceutical company can join. Contract runs from 01.08.2025 to 31.07.2027, with possible earlier termination. Submission requires signed contract, product list, and reliability declaration (paper or qualified electronic signature). No estimated value provided.

Risques

Open-house agreements may be superseded by other discount contracts, causing early termination without compensation.

Strict submission requirements (paper originals, qualified electronic signature, monthly deadlines) could slow down con...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies eligible.

Administrative

  • Submission of signed contract, product list ('Festlegung der vertragsgegenständlichen Arzneimittel'), and signed reliability declaration.
  • Acceptable submission methods: original paper (2 copies) or electronic with qualified electronic signature via DTVP portal.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – open house model: any eligible company can join.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Drug Discount Agreements Budesonid

Single lot covering Budesonid (ATC A07EA06) discount agreements. Non-exclusive, open to all eligible pharmaceutical companies. Contracting ongoing until 03.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – open house model: any eligible company can join.

Date limite

Deadline Jun 03, 2027

Détails de la procédure

Date de publication
15 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
387722-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30